Strathfield Retina Clinic | Strathfield, Australia

Research site

(Unclaimed)

Location

Suite 3A, 9 Redmyre Road, Strathfield, New South Wales, Australia

Site insights

Top conditions

Top treatments

Faricimab

APL-2

KHK4951

Triamcinolone Acetonide

Aflibercept

Ranibizumab

Pegcetacoplan

Dexamethasone

JNJ-81201887

IBE-814

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 19 total trials

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Enrolling

Geographic Atrophy

Drug: Triamcinolone

Other: Sham Procedure

A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (POYANG)

This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in pa...

Enrolling

Choroidal Neovascularization Secondary to Pathologic Myopia

Procedure: Sham Procedure

Drug: Faricimab

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR)

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...

Enrolling

Macular Edema Secondary to Retinal Vein Occlusion

Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg

Drug: Sham

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting

Geographic Atrophy Secondary to Age-related Macular Degeneration

Drug: PEGCETACOPLAN (APL-2)